Dravet症候群市場：製品別、発作タイプ別、重症度別、エンドユーザー別 - 2025-2030年の世界予測

Dravet症候群市場は、2023年に6億7,647万米ドルと評価され、2024年には7億3,404万米ドルに達すると予測され、CAGR 8.70％で成長し、2030年には12億1,321万米ドルに達すると予測されています。

Dravet症候群は、幼少期に発症するまれな壊滅的なてんかんであり、頻繁で長引く発作と発達の遅れを特徴とします。Dravet症候群治療の市場範囲には、医薬品、診断ツール、支持療法技術が含まれます。その必要性は、患者の複雑かつ高いアンメット・メディカル・ニーズから生じ、効果的な薬剤や管理ソリューションに対する需要を牽引しています。用途の多くは、フェンフルラミンのような抗けいれん薬や、根本的な遺伝的原因をターゲットにした治療法です。最終用途の範囲は、革新的なソリューションを通じて患者の転帰を最適化しようとする病院、診療所、研究機関に及ぶ。市場成長の主な影響要因としては、遺伝子研究の進展、認知度の向上、新規治療法の開発と承認を奨励するヘルスケア政策の支持などが挙げられます。遺伝子治療とバイオ医薬品の革新への継続的な投資は、潜在的なビジネスチャンスをもたらします。このような機会は、バイオテクノロジー企業や学術研究機関との強固なパートナーシップを優先させ、最先端の治療法を生み出すことで活用することができます。しかし、研究開発コストの高さ、規制の厳しさ、臨床試験に参加できる患者の限定といった課題が大きな障壁となっています。これらを効果的に乗り切るには、戦略的提携や規制プロセスを合理化する技術への投資が必要です。さらに、技術革新と研究に最適な分野には、新薬候補の探索、非侵襲的診断ツール、ヘルスケアへのアクセス性を高める遠隔医療ソリューションなどがあります。この市場に関する洞察から、主に活発な研究開発活動と効果的な治療法に対する強い需要によって、その高成長性が明らかになった。とはいえ、既存の治療法との競合、一部の地域における一般市民の認知度の低さ、償還の問題が成長の障害となっています。企業は、こうした革新的な分野を開拓し、流通網を最適化し、ヘルスケアプロバイダーや患者を対象とした教育イニシアチブを強化することで、市場での成功を促進することができます。全体として、Dravet症候群市場は、多面的な課題に正面から取り組む機敏なヘルスケア企業にとって、十分な成長の可能性を秘めています。

市場力学：急速に進化するDravet症候群市場の主要市場インサイトを公開

Dravet症候群市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 遺伝性疾患の解明を目的とした研究開発活動の増加
  • 希少疾患に対する意識の高まり
  • Dravet症候群の治療薬や薬剤の開発に対する支援的な規制環境
• 市場抑制要因
  • Dravet症候群に関連する治療費の高騰
• 市場機会
  • Dravet症候群治療薬および薬剤の遺伝子治療の進歩
  • 希少疾患研究への資金提供の増加
• 市場の課題
  • 誤診や正しい診断の遅れにつながる診断上の課題

ポーターのファイブフォース：Dravet症候群市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：Dravet症候群市場における外部からの影響の把握

外部マクロ環境要因は、Dravet症候群市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析Dravet症候群市場における競合情勢の把握

Dravet症候群市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックスのDravet症候群市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、Dravet症候群市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨Dravet症候群市場における成功への道筋を描く

Dravet症候群市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開発の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 遺伝性疾患の理解を目的とした研究開発活動の増加
    • 希少疾患に対する意識の高まり
    • Dravet症候群治療法と医薬品の開発を支援する規制環境
  • 抑制要因
    • Dravet症候群に関連する治療費の高騰
  • 機会
    • Dravet症候群治療法と薬剤の遺伝子治療の進歩
    • 希少疾患調査への資金提供増加
  • 課題
    • 診断上の課題により誤診や正しい診断の遅れが生じる
• 市場セグメンテーション分析
  • 提供：発作を管理し、発作の頻度を減らすための薬剤の普及
  • 最終用途：急性期の治療と管理、および専門機器へのアクセスの提供における病院の重要な役割
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 Dravet症候群市場：提供別

• 診断およびテストソリューション
  • 脳波
  • 遺伝子検査
  • MRIとCTスキャン
• 食事療法
• 医薬品
  • クロバザム
  • スティリペントール
  • バルプロ酸

第7章 Dravet症候群市場：発作タイプ別

• 脱力発作
• ミオクロニー発作
• 部分発作
• 光過敏性発作
• 強直間代発作

第8章 Dravet症候群市場：重症度別

• 軽度
• 適度
• 重度

第9章 Dravet症候群市場：最終用途別

• ホームケア
• 病院
• 専門クリニック

第10章 南北アメリカのDravet症候群市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のDravet症候群市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのDravet症候群市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 管理におけるSTK-001の画期的な有効性：臨床試験の包括的分析と将来の展望
  • FDAとTGAの承認により、Encoded Therapeuticsの遺伝子治療ETX101がDravet症候群の臨床試験に導入される
  • 腸脳軸調査のブレークスルー：ブルームサイエンスのBL-001がDravet症候群およびALSの治療における有望な第1相試験結果を示す
• 戦略分析と提言

企業一覧

• Biocodex S.A.
• Bloom Science, Inc.
• Cyberonics, Inc.
• Eisai Co., Ltd.
• Encoded Therapeutics
• Epygenix Therapeutics
• GW Pharmaceuticals by Jazz Pharmaceuticals plc
• Insys Therapeutics, Inc.
• Longboard Pharmaceuticals, Inc.
• OPKO Health Inc.
• Ovid Therapeutics Inc.
• PTC Therapeutics
• Sage Therapeutics
• Stoke Therapeutics
• Supernus Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Virpax Pharmaceuticals
• Xenon Pharmaceuticals
• Zogenix Inc by UCB

LIST OF FIGURES

• FIGURE 1. DRAVET SYNDROME MARKET RESEARCH PROCESS
• FIGURE 2. DRAVET SYNDROME MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DRAVET SYNDROME MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DRAVET SYNDROME MARKET DYNAMICS
• TABLE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ELECTROENCEPHALOGRAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MRI & CT SCANS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIETARY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ATONIC SEIZURES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MYOCLONIC SEIZURES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PARTIAL SEIZURES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PHOTOSENSITIVE SEIZURES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TONIC-CLONIC SEIZURES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 52. CANADA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 53. CANADA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 54. CANADA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 55. CANADA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. CANADA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 57. CANADA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 84. CHINA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 85. CHINA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 86. CHINA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 87. CHINA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. CHINA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 89. CHINA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 90. INDIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 91. INDIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 92. INDIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 93. INDIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. INDIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 95. INDIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 193. ITALY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 194. ITALY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 195. ITALY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 196. ITALY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 197. ITALY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 198. ITALY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 217. POLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 218. POLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 219. POLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 220. POLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 221. POLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 222. POLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 223. QATAR DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 224. QATAR DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 225. QATAR DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 226. QATAR DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 227. QATAR DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 228. QATAR DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 283. DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 284. DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

The Dravet Syndrome Market was valued at USD 676.47 million in 2023, expected to reach USD 734.04 million in 2024, and is projected to grow at a CAGR of 8.70%, to USD 1,213.21 million by 2030.

Dravet Syndrome is a rare, catastrophic form of epilepsy that begins in early childhood, characterized by frequent, prolonged seizures and developmental delays. The market scope for Dravet Syndrome treatment encompasses pharmaceuticals, diagnostic tools, and supportive care technologies. The necessity arises from the complex, high unmet medical needs of patients, driving demand for effective medications and management solutions. Applications mostly revolve around anti-seizure medications like Fenfluramine and therapies targeting the underlying genetic causes. The end-use scope spans hospitals, clinics, and research institutions eager to optimize patient outcomes through innovative solutions. Key influencing factors for market growth include advancements in genetic research, increasing awareness, and supportive healthcare policies that encourage development and approval of novel treatments. The ongoing investments in gene therapy and biopharmaceutical innovations present potential opportunities. These opportunities can be leveraged by prioritizing robust partnerships with biotech firms and academic research entities to create cutting-edge therapies. However, challenges such as high R&D costs, stringent regulatory frameworks, and limited availability of patients for clinical trials pose significant barriers. Navigating these effectively requires strategic collaborations and investment in technologies that streamline regulatory processes. Moreover, the best areas for innovation and research include exploring new drug candidates, non-invasive diagnostic tools, and telemedicine solutions that enhance healthcare accessibility. Insights into this market reveal its high-growth nature, primarily driven by intense R&D activities and a strong demand for effective remedies. Nevertheless, competition from existing treatment options, limited public awareness in some regions, and reimbursement issues are hurdles to growth. Companies can foster market success by tapping into these innovative areas, optimizing distribution networks, and enhancing education initiatives geared towards healthcare providers and patients. Overall, the Dravet Syndrome market presents ample growth potential for agile healthcare companies ready to meet the multifaceted challenges head-on.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dravet Syndrome Market

The Dravet Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in research and development activities aimed at understanding genetic disorders
  • Rising awareness of rare diseases
  • Supportive regulatory environments for developments in Dravet syndrome therapies and medications
• Market Restraints
  • High cost of treatment associated with Dravet syndrome
• Market Opportunities
  • Advancements in genetic therapy for Dravet syndrome therapies and medications
  • Increased funding for rare disease research
• Market Challenges
  • Diagnostic challenges leading to misdiagnosis or delays in correct diagnosis

Porter's Five Forces: A Strategic Tool for Navigating the Dravet Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dravet Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dravet Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dravet Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dravet Syndrome Market

A detailed market share analysis in the Dravet Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dravet Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dravet Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dravet Syndrome Market

A strategic analysis of the Dravet Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dravet Syndrome Market, highlighting leading vendors and their innovative profiles. These include Biocodex S.A., Bloom Science, Inc., Cyberonics, Inc., Eisai Co., Ltd., Encoded Therapeutics, Epygenix Therapeutics, GW Pharmaceuticals by Jazz Pharmaceuticals plc, Insys Therapeutics, Inc., Longboard Pharmaceuticals, Inc., OPKO Health Inc., Ovid Therapeutics Inc., PTC Therapeutics, Sage Therapeutics, Stoke Therapeutics, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Virpax Pharmaceuticals, Xenon Pharmaceuticals, and Zogenix Inc by UCB.

Market Segmentation & Coverage

This research report categorizes the Dravet Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Offering, market is studied across Diagnosis & Testing Solutions, Dietary Therapies, and Medications. The Diagnosis & Testing Solutions is further studied across Electroencephalogram, Genetic Testing, and MRI & CT Scans. The Medications is further studied across Clobazam, Stiripentol, and Valproate.
• Based on Seizure Type, market is studied across Atonic Seizures, Myoclonic Seizures, Partial seizures, Photosensitive Seizures, and Tonic-Clonic Seizures.
• Based on Severity, market is studied across Mild, Moderate, and Severe.
• Based on End-Use, market is studied across Homecare, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in research and development activities aimed at understanding genetic disorders
    • 5.1.1.2. Rising awareness of rare diseases
    • 5.1.1.3. Supportive regulatory environments for developments in Dravet syndrome therapies and medications
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of treatment associated with Dravet syndrome
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in genetic therapy for Dravet syndrome therapies and medications
    • 5.1.3.2. Increased funding for rare disease research
  • 5.1.4. Challenges
    • 5.1.4.1. Diagnostic challenges leading to misdiagnosis or delays in correct diagnosis
• 5.2. Market Segmentation Analysis
  • 5.2.1. Offering: Proliferation of medications to manage & reduce the frequency of seizures
  • 5.2.2. End-Use: Pivotal role of hospitals in treating and managing acute episodes and providing access to specialized equipment
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Dravet Syndrome Market, by Offering

• 6.1. Introduction
• 6.2. Diagnosis & Testing Solutions
  • 6.2.1. Electroencephalogram
  • 6.2.2. Genetic Testing
  • 6.2.3. MRI & CT Scans
• 6.3. Dietary Therapies
• 6.4. Medications
  • 6.4.1. Clobazam
  • 6.4.2. Stiripentol
  • 6.4.3. Valproate

7. Dravet Syndrome Market, by Seizure Type

• 7.1. Introduction
• 7.2. Atonic Seizures
• 7.3. Myoclonic Seizures
• 7.4. Partial seizures
• 7.5. Photosensitive Seizures
• 7.6. Tonic-Clonic Seizures

8. Dravet Syndrome Market, by Severity

• 8.1. Introduction
• 8.2. Mild
• 8.3. Moderate
• 8.4. Severe

9. Dravet Syndrome Market, by End-Use

• 9.1. Introduction
• 9.2. Homecare
• 9.3. Hospitals
• 9.4. Specialty Clinics

10. Americas Dravet Syndrome Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Dravet Syndrome Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Dravet Syndrome Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Breakthrough Efficacy of STK-001 in Dravet Syndrome Management: A Comprehensive Analysis of Clinical Trials and Future Prospects
  • 13.3.2. FDA and TGA Approval Ushers Encoded Therapeutics' Gene Therapy ETX101 into Clinical Trials for Dravet Syndrome
  • 13.3.3. Breakthrough in Gut-Brain Axis Research: Bloom Science's BL-001 Shows Promising Phase 1 Results for Treatment of Dravet Syndrome and ALS
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Biocodex S.A.
• 2. Bloom Science, Inc.
• 3. Cyberonics, Inc.
• 4. Eisai Co., Ltd.
• 5. Encoded Therapeutics
• 6. Epygenix Therapeutics
• 7. GW Pharmaceuticals by Jazz Pharmaceuticals plc
• 8. Insys Therapeutics, Inc.
• 9. Longboard Pharmaceuticals, Inc.
• 10. OPKO Health Inc.
• 11. Ovid Therapeutics Inc.
• 12. PTC Therapeutics
• 13. Sage Therapeutics
• 14. Stoke Therapeutics
• 15. Supernus Pharmaceuticals, Inc.
• 16. Takeda Pharmaceutical Company Limited
• 17. Virpax Pharmaceuticals
• 18. Xenon Pharmaceuticals
• 19. Zogenix Inc by UCB